248 related articles for article (PubMed ID: 33472433)
1. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Aquilanti E; Brastianos PK
Neurosurgery; 2020 Sep; 87(3):E281-E288. PubMed ID: 32302389
[TBL] [Abstract][Full Text] [Related]
7. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
12. [Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer].
Jacquin-Porretaz C; Nardin C; Puzenat E; Roche-Kubler B; Aubin F;
Presse Med; 2017 Sep; 46(9):808-817. PubMed ID: 28683958
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
[TBL] [Abstract][Full Text] [Related]
14. High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors--A nationwide register-based cohort study.
Sørup S; Darvalics B; Russo L; Oksen D; Lamy FX; Verpillat P; Aa K; Ht S; Cronin-Fenton D
Cancer Med; 2021 Jul; 10(14):4957-4963. PubMed ID: 34105315
[TBL] [Abstract][Full Text] [Related]
15. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
Li W; Yu H
J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.
Sperduto PW; Chao ST; Sneed PK; Luo X; Suh J; Roberge D; Bhatt A; Jensen AW; Brown PD; Shih H; Kirkpatrick J; Schwer A; Gaspar LE; Fiveash JB; Chiang V; Knisely J; Sperduto CM; Mehta M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):655-61. PubMed ID: 19942357
[TBL] [Abstract][Full Text] [Related]
18. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
Sánchez-Magraner L; Miles J; Baker CL; Applebee CJ; Lee DJ; Elsheikh S; Lashin S; Withers K; Watts AG; Parry R; Edmead C; Lopez JI; Mehta R; Italiano A; Ward SG; Parker PJ; Larijani B
Cancer Res; 2020 Oct; 80(19):4244-4257. PubMed ID: 32855204
[TBL] [Abstract][Full Text] [Related]
19. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
20. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]